Literature DB >> 30644817

Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.

Michael D Gray1, Paul C Lyon1, Christophoros Mannaris1, Lisa K Folkes1, Michael Stratford1, Leticia Campo1, Daniel Y F Chung1, Shaun Scott1, Mark Anderson1, Robert Goldin1, Robert Carlisle1, Feng Wu1, Mark R Middleton1, Fergus V Gleeson1, Constantin C Coussios1.   

Abstract

Purpose To demonstrate the feasibility and safety of using focused ultrasound planning models to determine the treatment parameters needed to deliver volumetric mild hyperthermia for targeted drug delivery without real-time thermometry. Materials and Methods This study was part of the Targeted Doxorubicin, or TARDOX, phase I prospective trial of focused ultrasound-mediated, hyperthermia-triggered drug delivery to solid liver tumors ( ClinicalTrials.gov identifier NCT02181075). Ten participants (age range, 49-68 years; average age, 60 years; four women) were treated from March 2015 to March 2017 by using a clinically approved focused ultrasound system to release doxorubicin from lyso-thermosensitive liposomes. Ultrasonic heating of target tumors (treated volume: 11-73 cm3 [mean ± standard deviation, 50 cm3 ± 26]) was monitored in six participants by using a minimally invasive temperature sensor; four participants were treated without real-time thermometry. For all participants, CT images were used with a patient-specific hyperthermia model to define focused ultrasound treatment plans. Feasibility was assessed by comparing model-prescribed focused ultrasound powers to those implemented for treatment. Safety was assessed by evaluating MR images and biopsy specimens for evidence of thermal ablation and monitoring adverse events. Results The mean difference between predicted and implemented treatment powers was -0.1 W ± 17.7 (n = 10). No evidence of focused ultrasound-related adverse effects, including thermal ablation, was found. Conclusion In this 10-participant study, the authors confirmed the feasibility of using focused ultrasound-mediated hyperthermia planning models to define treatment parameters that safely enabled targeted, noninvasive drug delivery to liver tumors while monitored with B-mode guidance and without real-time thermometry. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Dickey and Levi-Polyachenko in this issue.

Entities:  

Year:  2019        PMID: 30644817     DOI: 10.1148/radiol.2018181445

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  Deployable ultrasound applicators for endoluminal delivery of volumetric hyperthermia.

Authors:  Muhammad Zubair; Matthew S Adams; Chris J Diederich
Journal:  Int J Hyperthermia       Date:  2021-08-10       Impact factor: 3.914

Review 2.  Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.

Authors:  Khaled Mahmoud; Shady Swidan; Mohamed El-Nabarawi; Mahmoud Teaima
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

Review 3.  Ultrasound-induced biophysical effects in controlled drug delivery.

Authors:  Lulu Zhang; Zhuohua Lin; Lan Zeng; Fan Zhang; Lihong Sun; Suhui Sun; Ping Wang; Menghong Xu; Jinxia Zhang; Xiaolong Liang; Huiyu Ge
Journal:  Sci China Life Sci       Date:  2021-08-25       Impact factor: 6.038

4.  Novel fractionated ultrashort thermal exposures with MRI-guided focused ultrasound for treating tumors with thermosensitive drugs.

Authors:  Marc A Santos; Sheng-Kai Wu; Maximilian Regenold; Christine Allen; David E Goertz; Kullervo Hynynen
Journal:  Sci Adv       Date:  2020-09-02       Impact factor: 14.136

5.  The effect of injected dose on localized tumor accumulation and cardiac uptake of doxorubicin in a Vx2 rabbit tumor model using MR-HIFU mild hyperthermia and thermosensitive liposomes.

Authors:  Bingbing Cheng; Chenchen Bing; Robert M Staruch; Sumbul Shaikh; Michelle Wodzak Staruch; Debra Szczepanski; Noelle S Williams; Theodore W Laetsch; Rajiv Chopra
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

6.  Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.

Authors:  Hua Zhang; Wei-Lun Tang; Azadeh Kheirolomoom; Brett Z Fite; Bo Wu; Kenneth Lau; Mo Baikoghli; Marina Nura Raie; Spencer K Tumbale; Josquin Foiret; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; R Holland Cheng; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2020-11-13       Impact factor: 9.776

Review 7.  Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review.

Authors:  Nahid S Awad; Vinod Paul; Nour M AlSawaftah; Gail Ter Haar; Theresa M Allen; William G Pitt; Ghaleb A Husseini
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-03

Review 8.  Smart Targeting To Improve Cancer Therapeutics.

Authors:  Moraima Morales-Cruz; Yamixa Delgado; Kai Griebenow; Betzaida Castillo; Cindy M Figueroa; Anna M Molina; Anamaris Torres; Melissa Milián
Journal:  Drug Des Devel Ther       Date:  2019-10-30       Impact factor: 4.162

Review 9.  Droplet Microfluidics for Tumor Drug-Related Studies and Programmable Artificial Cells.

Authors:  Pantelitsa Dimitriou; Jin Li; Giusy Tornillo; Thomas McCloy; David Barrow
Journal:  Glob Chall       Date:  2021-05-07

10.  Mild hyperthermia by MR-guided focused ultrasound in an ex vivo model of osteolytic bone tumour: optimization of the spatio-temporal control of the delivered temperature.

Authors:  Pauline C Guillemin; Laura Gui; Orane Lorton; Thomas Zilli; Lindsey A Crowe; Stéphane Desgranges; Xavier Montet; Sylvain Terraz; Raymond Miralbell; Rares Salomir; Sana Boudabbous
Journal:  J Transl Med       Date:  2019-10-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.